Bilirubin Can Be Used as a Prognostic Factor for Lung Adenocarcinoma Patients with EGFR Mutations

BACKGROUND AND OBJECTIVES: Non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) mutation demonstrate only a median progression-free survival (PFS) of 8 to 10 months and undergo EGFR tyrosine kinase inhibitors (EGFR-TKIs) therapy. For decades, bilirubin has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Yimeng, Mei, Yeling, Xi, Ying, Yu, Junlin, Meng, Ke, Zhang, Tengfei, Ma, Wang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605630/
https://www.ncbi.nlm.nih.gov/pubmed/33149620
http://dx.doi.org/10.2147/OTT.S266477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605630/
https://www.ncbi.nlm.nih.gov/pubmed/33149620
http://dx.doi.org/10.2147/OTT.S266477

Ejemplares similares